Mega Lifesciences PCL (BKK:MEGA)
Thailand · Delayed Price · Currency is THB 35.00
0.00 (0.00%)
Sep 3, 2026, 4:36 PM ICT
Mega Lifesciences PCL Ratios and Metrics
Market cap in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 30,515 | 29,208 | 28,990 | 35,093 | 40,760 | 44,029 | |
Market Cap Growth | 25.00% | 0.75% | -17.39% | -13.90% | -7.43% | 41.26% |
Enterprise Value | 27,202 | 26,052 | 26,452 | 32,883 | 39,242 | 42,440 |
Last Close Price | 35.00 | 32.00 | 30.15 | 35.08 | 39.24 | 40.88 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.93 | 15.28 | 14.41 | 17.61 | 18.18 | 22.62 |
Forward PE | 12.99 | 13.07 | 11.29 | 14.52 | 17.76 | 22.85 |
PS Ratio | 2.10 | 2.06 | 1.88 | 2.23 | 2.59 | 3.11 |
PB Ratio | 2.95 | 2.86 | 2.94 | 3.77 | 4.64 | 5.49 |
P/TBV Ratio | 3.38 | 3.28 | 3.39 | 4.40 | 5.47 | 6.62 |
P/FCF Ratio | 13.80 | 13.87 | 13.46 | 21.25 | 24.09 | 17.10 |
P/OCF Ratio | 11.06 | 10.54 | 12.07 | 18.22 | 20.41 | 16.15 |
PEG Ratio | 5.90 | 43.58 | 30.40 | 2.85 | 3.23 | 1.41 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.87 | 1.84 | 1.72 | 2.09 | 2.50 | 3.00 |
EV/EBITDA Ratio | 8.24 | 8.26 | 7.32 | 10.45 | 13.45 | 17.84 |
EV/EBIT Ratio | 8.88 | 8.83 | 7.76 | 11.19 | 14.42 | 19.48 |
EV/FCF Ratio | 12.30 | 12.37 | 12.28 | 19.91 | 23.19 | 16.48 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.07 | 0.07 | 0.05 | 0.03 | 0.05 | 0.04 |
Debt / EBITDA Ratio | 0.21 | 0.21 | 0.13 | 0.08 | 0.14 | 0.15 |
Debt / FCF Ratio | 0.31 | 0.32 | 0.23 | 0.15 | 0.25 | 0.14 |
Net Debt / Equity Ratio | -0.32 | -0.39 | -0.34 | -0.27 | -0.27 | -0.27 |
Net Debt / EBITDA Ratio | -1.02 | -1.26 | -0.93 | -0.78 | -0.81 | -0.92 |
Net Debt / FCF Ratio | -1.50 | -1.88 | -1.56 | -1.49 | -1.41 | -0.85 |
Asset Turnover | 0.96 | 0.95 | 1.09 | 1.09 | 1.13 | 1.14 |
Inventory Turnover | 2.08 | 2.23 | 2.37 | 2.29 | 2.18 | 2.25 |
Quick Ratio | 1.48 | 1.59 | 1.79 | 1.40 | 1.10 | 1.08 |
Current Ratio | 2.20 | 2.23 | 2.61 | 2.26 | 1.91 | 1.92 |
Return on Equity (ROE) | 21.59% | 19.03% | 20.99% | 22.04% | 26.66% | 25.87% |
Return on Assets (ROA) | 12.66% | 12.30% | 15.05% | 12.77% | 12.19% | 10.97% |
Return on Invested Capital (ROIC) | 35.36% | 36.76% | 43.75% | 39.14% | 38.39% | 30.35% |
Return on Capital Employed (ROCE) | 28.50% | 27.70% | 33.10% | 30.30% | 29.90% | 25.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.18% | 6.55% | 6.94% | 5.68% | 5.50% | 4.42% |
FCF Yield | 7.25% | 7.21% | 7.43% | 4.71% | 4.15% | 5.85% |
Dividend Yield | 4.68% | 5.00% | 5.31% | 4.56% | 4.08% | 3.38% |
Payout Ratio | 63.69% | 72.96% | 69.30% | 72.23% | 62.71% | 47.41% |
Total Shareholder Return | 4.68% | 5.00% | 5.31% | 4.56% | 4.08% | 3.38% |